Cover Image

市場進入的影響:氣喘/COPD (美國)

Market Access Impact: Asthma/COPD (US)

出版商 FirstWord 商品編碼 344330
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
市場進入的影響:氣喘/COPD (美國) Market Access Impact: Asthma/COPD (US)
出版日期: 2016年09月01日 內容資訊: 英文



  • 對市場進入的各種障礙的影響
    • 醫生最大量開立處方的品牌是?
    • 受到各種障礙影響的處方箋數是?
    • 哪個障礙影響最大?
  • 障礙對各品牌的影響
    • 各品牌開立處方的醫生數是?沒打算開立處方但考慮的數量是?
    • 不開立處方的理由是?替代的處方是?
    • 各品牌的市場佔有率是?


  • Advair (fluticasone/salmeterol; GSK)
  • Anoro (umeclidinium/vilanterol; GSK)
  • Arcapta (indacaterol; Novartis)
  • Breo Ellipta (vilanterol/fluticasone furoate; GSK)
  • Daliresp (roflumilast; AstraZeneca)
  • Nucala (mepolizumab; GSK)
  • Seebri (glycopyrronium; Novartis)
  • Spiriva (tiotropium; Boehringer Ingelheim
  • Symbicort (budesonide/formoterol; AstraZeneca)
  • Tudorza (aclidinium; AstraZeneca)
  • Utibron (indacaterol/glycopyrronium; Novartis)
  • Xolair (omalizumab; Novartis/Roche)


Product Code: 596200653

Are market barriers helping or hindering your asthma/COPD brand's performance?

Three brands top the list in the US as the most prescribed treatments for asthma and COPD, but are these the preferred options or are market barriers pushing physicians toward them? Delve behind the headline numbers and find out the constraints impacting decision-making - to the benefit of some brands and the detriment of others.

This new report from FirstView, Market Access Impact: Asthma/COPD, assesses current barriers and their effects for 12 leading asthma/COPD drugs from GSK, Novartis, AstraZeneca, Boehringer Ingelheim and Roche.

Use this powerful insight into physician thinking to optimise your market access strategy and increase market penetration.

Key Questions Answered

  • Advair (fluticasone/salmeterol; GSK): If barriers to other brands were alleviated, how much market share would Advair lose?
  • Anoro (umeclidinium/vilanterol; GSK): Which is the biggest factor prompting lost share for Anoro?
  • Arcapta (indacaterol; Novartis): Which 3 brands should Arcapta focus on to win back market share?
  • Breo Ellipta (vilanterol/fluticasone furoate; GSK): How much share does Breo Ellipta stand to gain if current barriers are overcome?
  • Daliresp (roflumilast; AstraZeneca): Which 2 brands is Daliresp losing out to the most?
  • Nucala (mepolizumab; GSK): 15% of physicians cite at least 3 barriers influencing Nucala prescribing - lack of reimbursement tops the list, but what are the others?
  • Seebri (glycopyrronium; Novartis): What are the top 3 barriers to prescribing Seebri? Which other brand is benefiting the most?
  • Spiriva (tiotropium; Boehringer Ingelheim: Which of the brands surveyed is Spiriva gaining share from? Which competitors should be in the spotlight?
  • Symbicort (budesonide/formoterol; AstraZeneca): Which single brand is stealing the most share from Symbicort?
  • Tudorza (aclidinium; AstraZeneca): Tudorza is struggling to gain traction in this highly competitive market. Which competitors should the focus be on to tip the balance?
  • Utibron (indacaterol/glycopyrronium; Novartis): Is awareness an issue? What proportion of physicians surveyed say they are unaware of Utibron within the asthma/COPD landscape?
  • Xolair (omalizumab; Novartis/Roche): 81% of physicians cite one or multiple barriers to prescribing Xolair; which other brands are benefiting?

Top Takeaways

  • Barriers are significantly affecting market share: A notable proportion of all prescribing decisions are impacted by perceived barriers.
  • More losers than winners: Three brands see a net gain in market share, whilst the remaining nine are showing losses.
  • The ‘top-spot' is closely contested: Two brands are fighting a close battle on market share gains, but can they hold onto their leading position as market newcomers gain traction?
  • ‘Market-access' barriers have a significant effect: Reimbursement issues and lack of formulary availability together affect more prescriptions than any other barrier.
  • Newcomers are a threat to the status quo: If barriers were successfully overcome, two drugs could leap ahead.
  • ‘Other' brands benefiting: The remaining brands not included in this survey together achieve the third biggest net share gain thanks to prescribing barriers.
  • US and Europe differ: In terms of both the brands most prescribed and the effect barriers have on prescribing. See the EU5 report for details.

Exploring Market Access Issues

Market Access Impact: Asthma/COPD explores key issues affecting drug manufacturers. You'll learn:

How barriers affect market access:

  • Which brands are physicians prescribing for asthma/COPD?
  • How are barriers affecting prescribing decisions?
  • Which brands gain and lose the most market share?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don't, but would consider it?
  • Why don't doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 100 pulmonologists in the US, chosen from the largest community of validated physicians in the world. All respondents have:

  • Been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients with asthma/COPD in total in the last month

We conducted the survey between the 8th and 13th June 2016.

Back to Top